View Older Stories View More Recent Stories

Nov 2, 2023 04:05PM MDB Capital Holdings to Host Third Quarter 2023 Results Conference Call on November 15, 2023 at 4:30 PM Eastern Time

Oct 17, 2023 10:00AM Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth Cohort

Oct 11, 2023 11:10AM Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy

Sep 21, 2023 09:00AM MDB Capital Holdings Begins Trading on NASDAQ

Sep 21, 2023 06:02AM Form CERT MDB Capital Holdings,

Sep 20, 2023 09:00AM MDB Capital Holdings Announces Closing of Public Offering of $20 Million

Sep 20, 2023 06:06AM Form 8-K MDB Capital Holdings, For: Sep 20

Aug 30, 2023 11:06AM Form 424B3 MDB Capital Holdings,

Aug 30, 2023 11:05AM Form 424B3 MDB Capital Holdings,

Aug 30, 2023 06:02AM Form 10-Q MDB Capital Holdings, For: Jun 30

Aug 2, 2023 02:41PM Form 424B4 MDB Capital Holdings,

Aug 2, 2023 02:06PM Form 424B4 MDB Capital Holdings,

Aug 2, 2023 08:01AM Form 3 MDB Capital Holdings, For: Jul 23 Filed by: Meline Susanne

Aug 2, 2023 08:01AM Form 3 MDB Capital Holdings, For: Jul 25 Filed by: James Jeremy William

Aug 2, 2023 08:01AM Form 3 MDB Capital Holdings, For: Jul 25 Filed by: Magennis Sean James

Aug 2, 2023 08:01AM Form 3 MDB Capital Holdings, For: Jul 25 Filed by: HAYAT MOHAMMAD

Aug 2, 2023 08:01AM Form 3 MDB Capital Holdings, For: Jul 25 Filed by: MARLETT CHRISTOPHER A

Aug 2, 2023 08:01AM Form 3 MDB Capital Holdings, For: Jul 25 Filed by: Brandon George Hugh

Aug 2, 2023 08:01AM Form 3 MDB Capital Holdings, For: Jul 25 Filed by: DIGIANDOMENICO ANTHONY

Aug 2, 2023 08:01AM Form 3 MDB Capital Holdings, For: Jul 25 Filed by: Hayden Matthew

Aug 1, 2023 05:22PM Form SC 13D MDB Capital Holdings, Filed by: MARLETT CHRISTOPHER A

Aug 1, 2023 05:20PM Form SC 13D MDB Capital Holdings, Filed by: DIGIANDOMENICO ANTHONY

Jul 31, 2023 08:01AM Form 8-K MDB Capital Holdings, For: Jul 31

Jul 26, 2023 11:08AM Form 424B4 MDB Capital Holdings,

Jul 26, 2023 06:03AM Form EFFECT MDB Capital Holdings,

Jul 20, 2023 01:41PM Form 8-A12B MDB Capital Holdings,

Jul 20, 2023 01:41PM Form S-1/A MDB Capital Holdings,

Jul 6, 2023 03:25PM Form S-1/A MDB Capital Holdings,

Jun 20, 2023 05:56PM Paris finance summit to push development banks to take on more risk -draft

May 8, 2023 04:37PM Form S-1/A MDB Capital Holdings,

Mar 24, 2023 06:02AM Form S-1/A MDB Capital Holdings,

Feb 2, 2023 02:25PM Form S-1/A MDB Capital Holdings,

Jan 11, 2023 11:11AM Global Hemp Group Announces Execution of Binding LOI with Apollon Formularies PLC

Dec 28, 2022 05:10PM Form S-1/A MDB Capital Holdings,

Nov 29, 2022 09:00AM MDB Capital Holdings Announces Third MDB-Launched Company to Achieve FDA Approval

Nov 17, 2022 09:00AM Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)

Nov 17, 2022 09:00AM Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)

Nov 11, 2022 09:15AM MDB Capital Holdings Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq

Nov 11, 2022 05:37AM MDB Capital Holdings (MDBH) Announces 833K Share IPO at $12/sh

Nov 10, 2022 05:31PM Form S-1 MDB Capital Holdings,

Jun 23, 2022 06:00AM Form D MDB Capital Holdings,

May 24, 2022 09:00AM Know Labs Expands Leadership Team, Adds Chief Financial Officer and Chief Product Officer, As It Gets Closer to FDA Clearance Application

Oct 9, 2019 05:00AM Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

Jan 8, 2019 04:11PM Clearsign Combustion (CLIR) and Anthony DiGiandomenico Reach Pact to Refresh ClearSign's Board

Jan 8, 2019 04:05PM ClearSign and Anthony DiGiandomenico Reach Agreement to Refresh ClearSign's Board and Ensure Smooth Management Transition

Sep 10, 2018 05:54AM Sorrento Therapeutics (SRNE) Subsidiary Scilex Announces $140M in Non-Dilutive Royalty-Based Financing for Commercialization of Non-Opioid ZTlido Pain Medication

Sep 10, 2018 04:00AM Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication

Sep 4, 2018 08:00AM Form SC 13D/A Provention Bio, Inc. Filed by: MDB CAPITAL GROUP LLC

Jul 20, 2018 06:06AM Form SC 13D/A Provention Bio, Inc. Filed by: MDB CAPITAL GROUP LLC

Jul 19, 2018 07:33PM Form 4 Provention Bio, Inc. For: Jul 19 Filed by: MDB CAPITAL GROUP LLC

View More Recent Stories View Older Stories